Venture Media.nl - uw gids naar venture capital

Home   |  1001 Financieringen   |  Opinie en advies   |  Nieuwsarchief   |  Reageer
Venture Capital Gids   |  Stappenplan   |  Boekenoverzicht   |  Boeken Shop   |  Uitleg Begrippen
Venture Capital Gids
Lees meer: 34,95
Maak uw keuze uit de beste 100 Nederlandse investeerders.
Venture Capital Gids
Venture Capital Stappenplan
Lees meer: 30,95
Zet de eerste stap naar een kwaliteits- investeerder.
Venture Capital Stappenplan
Venture Capital Ranking
Lees meer: 19,95
Venture capital en business angels naar kwaliteit gerangschikt.
Venture Capital Ranking
Venture Capital Begrippen
Lees meer: 21,95
Het handige naslagwerk van de belangrijkste venture capital begrippen.
Venture Capital Begrippen
Lezing Waagkapitaal
Lees meer: 7,95
Het Ei van Columbus voor start-up-financiering.
Lezing Waagkapitaal

LSP participates in € 36 Million Series B Financing of Probiodrug AG

- AMSTERDAMS BIOTECH-INVESTERINGSBEDRIJF LEIDT INTERNATIONAAL SYNDICAAT

30-11-2009 - Onderzoek

LSP (Life Sciences Partners) today announced that it has participated in a € 36 million Series B financing round of Probiodrug AG, Halle/Saale (Germany). Probiodrug is a biotech company developing novel concepts and products for the treatment of neurodegenerative and inflammatory diseases with a special focus on Alzheimers disease.


LSP invested alongside BB Biotech, Edmond de Rothschild Investment Partners (EdRIP) and Biogen Idec New Ventures, all joining as new investors. The round found also strong support from all existing institutional shareholders - IBG Fonds, TVM Capital, HBM BioVentures, CFH Group as well as private investors.

Elhan Kosar from BB Biotech and Olivier Litzka from EdRIP will join the Company\'s Supervisory Board, Joerg Neermann from LSP, Rossella Medori from Biogen Idec New Ventures and Dallas Webb from BB Biotech will take observer seats.

“The funds will be used to further progress our innovative approaches, in particular of inhibiting the enzyme glutaminyl cyclase, and thereby keeping and further expanding our headstart in this emerging therapeutic approach,“ stated Hendrik Liebers, CFO of Probiodrug.“ This treatment concept had required significant efforts by Probiodrug to establish an integrated package consisting of advanced small-molecule drug candidates, new animal models reflecting the AD-hallmarks, neuronal loss and neuroinflammation, much better than existing models and a unique set of pharmacodynamic and biomarkers, which are needed to successfully develop into regulatory phases now,“ added Hans-Ulrich Demuth, CSO. “The novel concept has generated significant interest in academia and in the healthcare industry. Hence, we are glad to have assembled this blue chip consortium including our existing shareholders, which further underlines Probiodrug\'s unique positioning as a leading & promising Neurology & Immunology company,“ summarized Konrad Glund, CEO.







Venture Capital Nieuwsbrief

De laatste deals en adviezen in je mailbox!

Inhoud: Seed capital, early stage, groeikapitaal, nieuwe fondsen, awards, resultaten, adviezen.
Frequentie: Maandelijks
Bedrijfsnaam:
Uw naam:
Emailadres: *

N.B: In verband met probleemloze ontvangst, bij voorkeur GEEN GMAIL-adres



Ander venture capital nieuws:


Risicokapitaalinvesteringen sterk gestegen in 2011

Seed capital voor Ideedock

TomToms beursexit met behulp van Cyrte en Janivo

Goede resultaten Value8 over 2011

Intrinsic-ID Closes new Round with Robert Bosch Venture Capital and Prime Ventures

Value8 neemt belang van 5,32 procent in Euromedis

Antea neemt Tuinmeubelengroothandel Bukatchi over

IIZO Sushi gefinancieerd via MIND HUNTER

Prosensa Raises 23 Million in New Equity Financing

Peecho haalt durfgeld op bij twee investeerders


Bestand kan niet worden geopend.